Together, we can create a world
where people with diseases don’t
have to find therapies…
Therapies will find them.
At HVH, we empower healthcare companies by finding patients suffering from disease, before they are diagnosed.
HVH is shortening the time to diagnosis through the use of a proven and validated methodology to find diagnosed patients,
prospective therapy candidates, undiagnosed patients and ideal candidates for clinical trials so that innovative therapies
find the patients who desperately need them.
Our multidisciplinary team is comprised of problem solvers and industry experts in medical diagnostics, healthcare information
and advanced analytics bringing a unique and differentiated approach to connecting patients and therapies.
Chief Executive Officer
Steve is the Chief Executive Officer of HVH. Previously, he led Vencore Health Analytics and from January 2011 to
March 2017 was senior vice president and general counsel of Vencore, a 4,000-person organization that provides
information solutions, engineering and analysis to the U.S. Intelligence Community, Department of Defense and Civilian
Agencies. At different times, he led Vencore’s legal and ethics, corporate development, contracts, pricing, procurement
and property management organizations. Prior to joining Vencore, Steve was Counsel at Dechert LLP, an international
law firm, where he led teams structuring corporate acquisitions and dispositions, equity investments and complex
collaborations, with focus in the Life Sciences industry. Previously, Steve served as general counsel and head
of corporate development of Pharmacopeia, a public biopharmaceutical company. Steve graduated with honors from
Dartmouth College and from the Law School of the University of Pennsylvania. He is a member of the Board of Directors
and Chair of the Audit Committee of the Iraq and Afghanistan Veterans of America (IAVA), a leading post-9/11 veteran’s
Chief Data and Analytics Officer
Oodaye Shukla is the Chief Data and Analytics Officer for HVH. He has broad experience in the Healthcare, Telecom, DoD and the
Intelligence Community industries for over 20 years. Oodaye started his career at the Johns Hopkins Applied Physics
Lab building optical and digital computers, developing neural network models to objectively assess cataract severity.
He worked in the telecom industry at Lucent Technologies and at Siemens Telecom working on semiconductor lasers
and receivers, 1.6 TB/s optical long-haul systems, and having responsibility for a $20 Million product portfolio.
He joined Lockheed Martin (later becoming Vencore) in 2004, managing the development of a large-scale satellite
communications simulation model. He led the first efforts in finding undiagnosed rare disease patients that has
led to the formation of HVH. His educational background is BSEE from The Pennsylvania State University, MSEE (Optical
Signal Processing) from The John Hopkins University, MSEE (Neural Networks) from the University of Maryland, and
an MS in Technology Management from University of Pennsylvania/The Wharton School.
Dr. Pierantonio Russo, MD, FCPP, FAAP
Senior Vice President, Medical Affairs
Dr. Pierantonio Russo, MD, FCPP, FAAP is the Senior Vice President of Medical Affairs for HVH. Dr. Russo is a cardiac surgeon by training and trade and more recently a health care executive at national payer organizations. Dr. Russo attended Bologna Medical School and continued his training in Cardiovascular Surgery at Great Ormond Street Hospital and the Mayo Clinic, in Rochester, MN. From 1988 to 2007, he held academic, clinical and administrative leadership positions as: Chief of Cardiac Surgery and Heart Transplantation, Director of the Heart Institute and Director of the Cardiac Intensive Care Unit at St. Christopher’s Hospital for Children; Chief of Cardiac Surgery and Surgical Director of the CICU at the University of Missouri Hospital. Dr. Russo spent over 10 years in senior medical positions at Independence Blue Cross and Harvard Pilgrim payer systems.
Dr. Russo has personally performed 54 pediatric heart transplants in Philadelphia, PA. Additionally, Dr. Russo has held full-time academic positions in surgery and pediatrics at Temple Medical School, Thomas Jefferson Medical College, Allegheny University and the University of Missouri as well as in postgraduate MBA programs at the Wharton School of Business (International Program) and with Harvard Medical School faculty as a lecturer on the topic of population medicine.
Dr. Russo is a fellow of the College of Physicians of Philadelphia, Fellow of the American Academy of Pediatrics (Cardiology and CT) and a member of the Society of Thoracic Surgeons. Dr. Russo has been first author/co-author of 55 peer reviewed publications, in addition to authoring meeting abstracts and presenting at professional medical societies worldwide. Dr. Russo also sits on the advisory board of various healthcare organizations.
Rob is the Vice President, Operations for HVH. Prior to joining HVH, Rob was the VP - Business Operations Management
for Covance, Inc.’s Clinical Development Services business unit. Earlier in his career, Rob served as the Executive
Director - Process Excellence and Change Management and as the Director - IT Portfolio Management for the Covance
Corporate IT organization. Prior to joining Covance, Rob held roles of increasing responsibility for Accenture
Ltd. During his 12-year career with Accenture, Rob provided process, technology and human capital consulting services
to top-tier biopharmaceutical companies, primarily in the areas of Research and Development, Commercial Operations,
Supply Chain Management and Finance Operations. Rob graduated with honors from Boston University’s College of Engineering
with a degree in Mechanical Engineering.
Chief Commercial Officer
Mark is the Chief Commercial Officer for HVH. Mark is a 30+ year veteran in Pharmaceutical Marketing, Communications,
and Sales … focusing on insights and experiences that centers on satisfying customers’ needs. Mark has spearheaded
large custom research initiatives, across therapeutic areas with a focus in oncology, multi-cultural efforts &
insights, and large consumer audits, and has run global account, sales & service teams throughout his career. Most
recently, Mark was Executive VP, Global Head of Sales and responsible for the Global Commercial Operations of SERMO.
Prior to SERMO, Mark was one of the early stage Executives and headed the Global Sales of a Start-up company in
the agile micro-survey market research space: InCrowd, Inc. Prior experience for Mark includes EVP Sales at Healthcare
Research & Analytics, Phoenix Healthcare and GfK, where Mark was Sr. VP, Group Manager. The lions-share of Mark's
early career was spent as owner of Encore!, Inc. one of the premiere media and communication companies during the
1980's and early 1990's.
Senior Director, Finance
Jennifer Furniss is the Senior Director of Finance for HVH Precision Analytics. Prior to joining HVH, Jennifer was the Director of Financial Planning & Analysis for Perspecta. Jennifer has over 20 years of diverse business experience with a focus on financial analysis and reporting, cash management, long range planning, risk and opportunity management, acquisition integrations, system implementations and business process improvement.
Jennifer holds a Bachelor of Business Administration in Finance from Kent State University, a Master of Business Administration from Kent State University and a Master of Arts in International Business from Groupe École Supérieure de Commerce de Rennes, France.
Sophisticated analytics and predictive modeling can provide you with unique data and insights
Contact us to learn more and for a demo of how we can put our proven, patent-pending process to work to help your therapies
reach the patients who need them and help end the cycle of suffering.